Devonian Health Group Inc. Stock

Equities

GSD

CA2518341078

Pharmaceuticals

Market Closed - Toronto S.E. 03:01:37 2024-04-23 pm EDT 5-day change 1st Jan Change
0.22 CAD 0.00% Intraday chart for Devonian Health Group Inc. 0.00% +51.72%
Sales 2022 2.31M 1.69M Sales 2023 2.35M 1.71M Capitalization 39.73M 29.04M
Net income 2022 -3M -2.19M Net income 2023 -4M -2.92M EV / Sales 2022 24.1 x
Net cash position 2022 3.53M 2.58M Net cash position 2023 1.39M 1.02M EV / Sales 2023 16.3 x
P/E ratio 2022
-15.5 x
P/E ratio 2023
-8.09 x
Employees 7
Yield 2022 *
-
Yield 2023
-
Free-Float 85.8%
More Fundamentals * Assessed data
Dynamic Chart
Current month+2.33%
1 month+4.76%
3 months+22.22%
Current year+51.72%
More quotes
1 week
0.22
Extreme 0.22
0.22
1 month
0.22
Extreme 0.215
0.25
Current year
0.13
Extreme 0.125
0.25
1 year
0.11
Extreme 0.11
0.28
3 years
0.00
Extreme 0
0.70
5 years
0.00
Extreme 0
0.70
10 years
0.00
Extreme 0
0.95
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 23-03-16
Director of Finance/CFO - 15-12-27
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chief Tech/Sci/R&D Officer - 15-03-26
Chief Executive Officer 64 23-03-16
Director/Board Member 62 Feb. 27
More insiders
Date Price Change Volume
24-04-23 0.22 0.00% 8,500

Delayed Quote Toronto S.E., April 23, 2024 at 03:01 pm EDT

More quotes
Devonian Health Group Inc. is a Canada-based late-stage botanical pharmaceutical company. The Company's main activity is the development of botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases, including ulcerative colitis and atopic dermatitis. It is also involved in the development of value-added products for dermo-cosmetics and the distribution of pharmaceutical products through its subsidiary. The Company’s flagship product, Thykamine, the pharmaceutical product issued from its SUPREX platform, is a product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The Company’s flagship product, Thykamine, the pharmaceutical product issued from its SUPREX platform, is a product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The Company's cosmeceutical products include R-Spinasome and Purgenesis.
More about the company